Browse studies

Find your next paid study

34 recruiting studies matching your filters

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)

Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis

Severe Hemophilia A

Estimated

~$10 – $8,750

OctapharmaNCT05935358

Phase 1

BeCoMe-9: A Phase 1/2 Dose Escalation and Expansion Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of …

Hemophilia BHemophilia B, Moderately Severe or Severe

Estimated

~$10 – $8,750

Be BiopharmaNCT06611436

Phase 1

Assessment of Safety and Preliminary Efficacy of ASC618 in Subjects With Severe and Moderately Severe Hemophilia A

Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics. The major c…

Hemophilia A

Estimated

~$10 – $8,750

ASC TherapeuticsNCT04676048

American Thrombosis and Hemostasis Network ATHNdataset Registry

The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of li…

HemophiliaThrombosisHemophilia A+6 more

Estimated

~$10 – $1,125

American Thrombosis and Hemostasis NetworkNCT06820515

An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients With Hemophilia B

This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients …

Hemophilia B

Estimated

~$10 – $7,500

CSL BehringNCT06008938

Phase 1

Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study

Tranexamic acid (TXA) is a fibrinolytic inhibitor which prevents prolonged bleeding by interfering with fibrin clot breakdown by competitively binding to lysin…

HemophiliaHemorrhageFacelift Surgery

Estimated

~$10 – $6,250

University of MinnesotaNCT06345833

Hemophilia A Research Program (HARP): An Observational Intergenerational Cohort Study of Hemophilia A and Factor VIII Immunogenicity

This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood. Because the study fol…

Hemophilia AHemophilia A, SevereFactor VIII (FVIII)+10 more

Estimated

~$10 – $750

University of WashingtonNCT07414511

Phase 1

Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous b…

Von Willebrand Disease, Type 3Concomitant VWD and Hemophilia

Estimated

~$10 – $7,500

Bleeding and Clotting Disorders Institute Peoria, IllinoisNCT05500807

Phase 4

Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are e…

Hemophilia A With InhibitorHemophilia B With Inhibitor

Estimated

~$10 – $7,500

American Thrombosis and Hemostasis NetworkNCT04647227

Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A

The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patient…

Hemophilia A

Estimated

~$10 – $1,050

Washington Institute for CoagulationNCT04131036